Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in Pediatric Moderately to Severely Active Ulcerative Colitis
NCT07470879Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- May 2026
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of etrasimod in ulcerative colitis (UC), sponsored by Pfizer. Started May 2026; status: recruiting.
02
Drugs
etrasimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07470879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07470879.